What To Expect in a MacTel Imaging Exam

April 29, 2024 The following information was sent out via email to people who registered in the LMRI Contact Database.   This post will explain some (but not all) of the imaging exams that your eye doctor may perform during a screening or follow up visit for MacTel, and possible results of those tests. Further tests,… View Article

MacTel SAFE Study

March 6, 2024 The following information was sent out via email to people who registered in the LMRI Contact Database.   LMRI is conducting the SAFE study (Phase 2a Study of the Effect of Serine Supplementation and Fenofibrate Treatment on Serum Deoxysphinganine Levels in Patients with Macular Telangiectasia (MacTel) Type 2). The study aims to determine… View Article

MacTel Project 2023 Annual Meeting Summary

February 6, 2024 The following information was sent out via email to people who registered in the LMRI Contact Database.   The MacTel Project is an international research effort whose goal is to find the causes of, and treatments for, macular telangiectasia type 2.  The project was established in 2004 and is overseen by the Lowy… View Article

Positive Phase 3 Topline Results Announced for NT-501 Implant in MacTel

November 2, 2022 Neurotech Pharmaceuticals, Inc. announces positive Phase 3 topline results for NT-501 implant in macular telangiectaisa type 2 (MacTel).  (Cumberland, RI) Clinically relevant and statistically significant primary results with the NT-501 implant demonstrated change in the rate of progression of disease in Macular telangiectasia type 2 (MacTel) patients in two pivotal Phase 3… View Article

MacTel Project 2021 Update

LOWY MEDICAL RESEARCH INSTITUTE – LMRI This past year has surely been an interesting and challenging one.  We hope that you and your family, friends, neighbors, and coworkers were able to weather the events safely. Despite the many challenges presented by the pandemic, all our investigators and clinical sites are to be commended for continuing… View Article

CNTF Phase 3 Trial Enrollment Complete

September 21, 2020 Neurotech Pharmaceuticals, with support from the Lowy Medical Research Institute, is conducting a Phase 3 clinical trial testing ciliary neurotrophic factor (CNTF) in patients with macular telangiectasia type 2.  This is a multi-center trial, with clinical sites in the United States, Europe, and Australia. The clinical trial tests whether CNTF, a small… View Article

CNTF Clinical Trials: COVID-19 Update

March 24, 2020 The rapid spread of COVID-19 has disrupted many standard clinical operations, including the LMRI/Neurotech Phase 1, 2, and 3 clinical trials testing CNTF in MacTel. If you have questions regarding upcoming appointments or other study-related questions and are having trouble reaching the study team, please use our contact page and we will assist… View Article

Phase 3 Trial Currently Enrolling MacTel Patients

Neurotech Pharmaceuticals, with support from the Lowy Medical Research Institute, is currently enrolling a Phase 3 clinical trial testing ciliary neurotrophic factor (CNTF) in patients with macular telangiectasia type 2.  This is a multi-center trial, with clinical sites in the United States, Europe, and Australia. How do I Participate? You may contact a clinical site… View Article

The Latest MacTel Research: What does it mean for patients?

Scientists at the Lowy Medical Research Institute and their collaborators recently published an article describing a role for serine and toxic lipids in macular telangiectasia type 2.  The article, “Serine and Lipid Metabolism in Macular Disease and Peripheral Neuropathy,” was published online by the New England Journal of Medicine on September 11, 2019.1 The findings… View Article

Lowy Medical Research Institute scientists find cause of debilitating eye disease

15-year effort points to treatments to help MacTel patients and offers potential new insights into other eye diseases LA JOLLA, CA–September 11, 2019– Scientists at the Lowy Medical Research Institute (LMRI) have discovered one cause of a progressive, debilitating eye disease called macular telangiectasia type 2 (MacTel). The work, using genetic, clinical and biochemical studies… View Article